About Urigen Pharmaceuticals
Urigen Pharmaceuticals is a Healthcare company based in North Brunswick (United States) founded in 1997. It operates as a pain relief products for urological ailments are developed and tested. Urigen Pharmaceuticals has raised $3.02 million across 6 funding rounds. Urigen Pharmaceuticals offers products and services including Commercial Cleaning, Office Cleaning, Industrial Cleaning, Carpet Cleaning, and Fogging and Disinfection. Its focus areas include Life Sciences, Genitourinary Disorders and Drugs. Its competitors include Esprit Pharma, Lipella, Regenfro Co, Kissei Pharmaceutical and NEXT Life Sciences and 5 more; 7 of its 10 listed competitors have raised funding.
Company details
Urigen Pharmaceuticals is a developer of pain relief products for patients with urological ailments. It is a clinical stage urology focused specialty pharmaceutical company. It specializes in the design and implementation of products for patients with urological ailments specifically, the development of products for the amelioration of Painful Bladder Syndrome (PBS), Urethritis, Nocturia, and Over Active Bladder (OAB). The companys lead product URG-101, an intravesicular product for ICBPS symptoms and is in Phase II trials while the other product URG-501, an oral version of URG-101 is in the preclinical stage.
- Headquarters North Brunswick, United States
- SectorsHealthcare
- Website urigen.com
- Social LinkedIn
- Total Equity Funding$3.02M (USD)
in 6 rounds
- Latest Funding Round$3.02M (USD), Series A
Nov 2020
Products & Services of Urigen Pharmaceuticals
Urigen Pharmaceuticals offers a comprehensive portfolio of products and services, including Commercial Cleaning, Office Cleaning, Industrial Cleaning, Carpet Cleaning, and Fogging and Disinfection.
Cleans commercial properties for hygiene and maintenance.
Provides regular cleaning for office environments.
Removes dirt and ensures safety in industrial settings.
Revives carpets in commercial spaces for better appearance.
Uses technology to eliminate germs in business areas.
Funding Insights of Urigen Pharmaceuticals
Urigen Pharmaceuticals has successfully raised a total of $3.02M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $3.02 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.02M
- Total Rounds 6
- Last Round Series A — $3.02M
- First Round $750,000
(Jul 2013)
All 6 funding rounds of Urigen Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2020 | $3.02M | Series A | – | – | – |
| Feb 2018 | $1.38M | Unspecified | – | – | – |
| Apr 2017 | $500,000 | Unspecified | – | – | – |
| Jul 2015 | $300,000 | Unspecified | – | – | – |
| Oct 2013 | $856,000 | Unspecified | – | – | – |
| Jul 2013 | $750,000 | Debt – Conventional | – | – | – |
People of Urigen Pharmaceuticals
2 people are tracked at Urigen Pharmaceuticals (1 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Dan Vickery | CEO | Leadership |
Carlo J. Di Fonzo | Leadership | Team |
Complete people profiles for Urigen Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Urigen Pharmaceuticals
3 dated milestones of Urigen Pharmaceuticals across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Urigen Pharmaceuticals is founded.
- Funding First funding round of $750K.
- Funding Latest funding round, Series A, of $3.0M.
Competitors of Urigen Pharmaceuticals
Urigen Pharmaceuticals has 10 listed competitors in our database, 7 of them funded. They include Esprit Pharma, Lipella, Regenfro Co, Kissei Pharmaceutical and NEXT Life Sciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| espritpharma.com | 2005 | East Brunswick, United States | $219.49M | – | Develop drugs for genitourinary (GU) disorders | |
| lipella.com | 2005 | Pittsburgh, United States | $3.37M | 5 | Lipid-based therapies for common bladder syndromes are developed. | |
| regenephro.co.jp | 2019 | Kyoto, Japan | $28.88M | – | Developer of therapeutics to treat renal diseases | |
| kissei.co.jp | 1946 | Matsumoto, Japan | – | – | Therapies for renal diseases and urology-related anemia are developed. | |
| nextlifesciences.org | 2021 | San Luis Obispo, United States | $4.05M | – | Male contraception procedures are developed via Vasalgel technology. | |
| theravida.com | 2005 | San Mateo, United States | $12.5M | – | Clinical stage biopharma company developing drugs for urology and central nervous system disorders | |
| regrow.in | 2009 | Mumbai, India | $2.84M | 72 | Regrow Biosciences is engaged in regenerative cell therapy solutions. | |
| urovant.com | 2017 | Irvine, United States | – | – | Therapies for urological disorders such as overactive bladder are developed. | |
| aceruspharma.com | 2008 | Mississauga, Canada | $38.07M | – | Develops pharmaceuticals for urology, hormone replacement therapy, and female sexual dysfunction treatments. | |
| mukocell.com | 2013 | Dortmund, Germany | – | – | Developer of stem cell based therapy to reconstruct organs |
Detailed competitors of Urigen Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genitourinary Disorders
10 companies that operate in the same segment as Urigen Pharmaceuticals (Genitourinary Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | – | – | |
Provider of surgical devices for vertical hernia repair and abdominal wall reconstruction | 2012 | Malvern, Pennsylvania, United States | USD 104.6 M | USD 80.28 M | 209 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Miniaturized injectable neuromodulation devices are developed for chronic diseases. | 2014 | Santa Clara, California, United States | USD 123.59 M | – | – | |
Developer of a therapeutic solution to treat prostate, kidney, and bladder cancer | 2018 | Maple Grove, Minnesota, United States | USD 157 M | – | 29 | |
A device is developed to treat urinary obstruction from BPH. | 2014 | Palo Alto, California, United States | USD 48 M | – | 25 | |
Minimally invasive devices in urology | 2004 | Mountain View, California, United States | USD 137.96 M | – | 119 | |
Diagnostic devices for lower urinary tract diseases are developed. | 2021 | Aliso Viejo, California, United States | USD 94.99 M | – | 23 | |
Medical device for benign prostatic hyperplasia treatment is developed. | 2021 | Milwaukee, Wisconsin, United States | USD 54.16 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Urigen Pharmaceuticals
Urigen Pharmaceuticals was founded in 1997 and raised its 1st funding round 16 years after it was founded.
Urigen Pharmaceuticals is headquartered in North Brunswick, United States. It is registered at North Brunswick, New Jersey, United States.
Urigen Pharmaceuticals is a funded company, having raised a total of $3.02M across 6 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $750K, raised on Jul 2013.
Urigen Pharmaceuticals is a developer of pain relief products for patients with urological ailments. It is a clinical stage urology focused specialty pharmaceutical company. It specializes in the design and implementation of products for patients with urological ailments specifically, the development of products for the amelioration of Painful Bladder Syndrome (PBS), Urethritis, Nocturia, and Over Active Bladder (OAB). The companys lead product URG-101, an intravesicular product for ICBPS symptoms and is in Phase II trials while the other product URG-501, an oral version of URG-101 is in the preclinical stage.
Urigen Pharmaceuticals's top competitors include Lipella, Kissei Pharmaceutical and Regenfro Co.
Urigen Pharmaceuticals offers Commercial Cleaning, Office Cleaning, Industrial Cleaning, Carpet Cleaning, and Fogging and Disinfection.